L Degenhardt1, W Hall, M Warner-Smith. 1. National Drug and Alcohol Research Centre, University of New South Wales, Sydney NSW 2052, Australia. l.degenhardt@unsw.edu.au
Abstract
BACKGROUND: Injecting drug use (IDU) and associated mortality appear to be increasing in many parts of the world. IDU is an important factor in HIV transmission. In estimating AIDS mortality attributable to IDU, it is important to take account of premature mortality rates from other causes to ensure that AIDS related mortality among injecting drug users (IDUs) is not overestimated. The current review provides estimates of the excess non-AIDS mortality among IDUs. METHOD: Searches were conducted with Medline, PsycINFO, and the Web of Science. The authors also searched reference lists of identified papers and an earlier literature review by English et al (1995). Crude mortality rates (CMRs) were derived from data on the number of deaths, period of follow up, and number of participants. In estimating the all-cause mortality, two rates were calculated: one that included all cohort studies identified in the search, and one that only included studies that reported on AIDS deaths in their cohort. This provided lower and upper mortality rates, respectively. RESULTS: The current paper derived weighted mortality rates based upon cohort studies that included 179 885 participants, 1,219,422 person-years of observation, and 16,593 deaths. The weighted crude AIDS mortality rate from studies that reported AIDS deaths was approximately 0.78% per annum. The median estimated non-AIDS mortality rate was 1.08% per annum. CONCLUSIONS: Illicit drug users have a greatly increased risk of premature death and mortality due to AIDS forms a significant part of that increased risk; it is, however, only part of that risk. Future work needs to examine mortality rates among IDUs in developing countries, and collect data on the relation between HIV and increased mortality due to all causes among this group.
BACKGROUND: Injecting drug use (IDU) and associated mortality appear to be increasing in many parts of the world. IDU is an important factor in HIV transmission. In estimating AIDS mortality attributable to IDU, it is important to take account of premature mortality rates from other causes to ensure that AIDS related mortality among injecting drug users (IDUs) is not overestimated. The current review provides estimates of the excess non-AIDS mortality among IDUs. METHOD: Searches were conducted with Medline, PsycINFO, and the Web of Science. The authors also searched reference lists of identified papers and an earlier literature review by English et al (1995). Crude mortality rates (CMRs) were derived from data on the number of deaths, period of follow up, and number of participants. In estimating the all-cause mortality, two rates were calculated: one that included all cohort studies identified in the search, and one that only included studies that reported on AIDS deaths in their cohort. This provided lower and upper mortality rates, respectively. RESULTS: The current paper derived weighted mortality rates based upon cohort studies that included 179 885 participants, 1,219,422 person-years of observation, and 16,593 deaths. The weighted crude AIDS mortality rate from studies that reported AIDS deaths was approximately 0.78% per annum. The median estimated non-AIDS mortality rate was 1.08% per annum. CONCLUSIONS: Illicit drug users have a greatly increased risk of premature death and mortality due to AIDS forms a significant part of that increased risk; it is, however, only part of that risk. Future work needs to examine mortality rates among IDUs in developing countries, and collect data on the relation between HIV and increased mortality due to all causes among this group.
Authors: Kachit Choopanya; Don C Des Jarlais; Suphak Vanichseni; Dwip Kitayaporn; Philip A Mock; Suwanee Raktham; Krit Hireanras; William L Heyward; Sathit Sujarita; Timothy D Mastro Journal: J Acquir Immune Defic Syndr Date: 2002-01-01 Impact factor: 3.731
Authors: N Walker; J Stover; K Stanecki; A E Zaniewski; N C Grassly; J M Garcia-Calleja; P D Ghys Journal: Sex Transm Infect Date: 2004-08 Impact factor: 3.519
Authors: Vu Minh Quan; Nguyen Le Minh; Tran Viet Ha; Nguyen Phuong Ngoc; Pham The Vu; David D Celentano; Tran Thi Mo; Vivian F Go Journal: Addiction Date: 2010-11-04 Impact factor: 6.526
Authors: Han-Zhu Qian; Samuel E Stinnette; Peter F Rebeiro; Aaron M Kipp; Bryan E Shepherd; Charles P Samenow; Cathy A Jenkins; Paul No; Catherine C McGowan; Todd Hulgan; Timothy R Sterling Journal: J Subst Abuse Treat Date: 2011-02-23
Authors: Jennifer R Havens; Carrie B Oser; Hannah K Knudsen; Michelle Lofwall; William W Stoops; Sharon L Walsh; Carl G Leukefeld; Alex H Kral Journal: Drug Alcohol Depend Date: 2010-12-03 Impact factor: 4.492
Authors: John Macleod; Lorraine Copeland; Matthew Hickman; James McKenzie; Jo Kimber; Daniela De Angelis; James R Robertson Journal: BMC Public Health Date: 2010-02-26 Impact factor: 3.295
Authors: Jo Kimber; Lorraine Copeland; Matthew Hickman; John Macleod; James McKenzie; Daniela De Angelis; James Roy Robertson Journal: BMJ Date: 2010-07-01
Authors: Elena Losina; Bruce R Schackman; Sara N Sadownik; Kelly A Gebo; Rochelle P Walensky; John J Chiosi; Milton C Weinstein; Perrin L Hicks; Wendy H Aaronson; Richard D Moore; A David Paltiel; Kenneth A Freedberg Journal: Clin Infect Dis Date: 2009-11-15 Impact factor: 9.079